Gene Bridges Licenses Recombineering Technology to Daiichi Sankyo Co., Ltd.
“We are very pleased to welcome another major Japanese pharmaceutical company as a licensee of Red/ET,” commented Gary Stevens, CEO of Gene Bridges GmbH. “Recombineering is becoming the technology of choice in DNA engineering and with the help of Daiichi Sankyo Co., Ltd., we expect to gain further acceptance of Red/ET in industry and academia worldwide.”
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.